anandamide and Squamous-Cell-Carcinoma-of-Head-and-Neck

anandamide has been researched along with Squamous-Cell-Carcinoma-of-Head-and-Neck* in 1 studies

Other Studies

1 other study(ies) available for anandamide and Squamous-Cell-Carcinoma-of-Head-and-Neck

ArticleYear
Human laryngeal squamous cell carcinoma cell line release of endogenous anandamide and 2-arachidonoylglycerol, and their antiproliferative effect via exogenous supplementation: an in vitro study.
    Cell and tissue banking, 2022, Volume: 23, Issue:1

    The level of the major endocannabinoids anandamide (AEA) and 2-arachidonoylglycerol (2-AG) are altered in several types of carcinomas, and are known to regulate tumor growth. Thusly, this study hypothesized that the HEp-2 human laryngeal squamous cell carcinoma (LSCC) cell line releases AEA and 2-AG, and aimed to determine if their exogenous supplementation has an anti-proliferative effect in vitro. In this in vitro observational study a commercial human LSCC cell line (HEp-2) was used to test for endogenous AEA and 2-AG release via liquid chromatography-tandem mass spectrometry (LC-MS/MS). The anti-proliferative effect of AEA and 2-AG supplementation was evaluated via WST-1 proliferation assay. It was observed that the HEp-2 LSCC cell line released AEA and 2-AG; the median quantity of AEA released was 15.69 ng mL

    Topics: Arachidonic Acids; Cell Line; Chromatography, Liquid; Dietary Supplements; Endocannabinoids; Glycerides; Head and Neck Neoplasms; Humans; Polyunsaturated Alkamides; Squamous Cell Carcinoma of Head and Neck; Tandem Mass Spectrometry

2022
chemdatabank.com